IL-15 and IL-15 super-agonist ALT803 exhibit capabilities to increase NK cell cytotoxicity in AML patients (166) and other tumor models such as advanced solid tumors (NCT01946789), multiple myeloma (NCT02099539), relapsed hematologic malignancy (NCT01885897) (27) and metastatic NSCLC (NCT02989844) (167). This evidence concerns the gene IL15 and plasma cell myeloma.